Congenital ADAMTS13 deficiency: a rare mimicker of immune thrombocytopenic purpura.

Congenital ADAMTS13 deficiency is a rare disease that leads to recurrent episodes of thrombotic thrombocytopenic purpura. We report a case that mimicked a recurring immune thrombocytopenic purpura in a child. Mild cases of ADAMTS13 deficiency may be initially confused with immune thrombocytopenic purpura if hemolytic anemia is not severe and renal or neurological symptoms are not present. Fresh frozen plasma is the treatment of choice in acute thrombotic thrombocytopenic purpura in ADAMTS13-deficient patients. The best long-term treatment for slightly symptomatic cases remains to be elucidated. Recombinant human ADAMTS13 factor will be a promising option when commercially available.

[1]  R. Gibbs,et al.  Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. , 2012, Blood.

[2]  T. Miyata,et al.  Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan , 2011, Journal of thrombosis and haemostasis : JTH.

[3]  F. Peyvandi,et al.  ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura , 2010, Human mutation.

[4]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children , 2009, Pediatric Nephrology.

[5]  K. Moon,et al.  Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease , 2008, Pediatric Nephrology.

[6]  H. Born,et al.  Inherited ADAMTS13 deficiency: Unique presentation and treatment , 2008, Pediatric blood & cancer.

[7]  G. Buchanan.  Thrombocytopenia during childhood: what the pediatrician needs to know. , 2005, Pediatrics in review.

[8]  J. Willert,et al.  Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. , 2004, Journal of pediatric hematology/oncology.

[9]  B. Lämmle,et al.  ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor‐cleaving protease activity by recombinant human ADAMTS13 , 2003, British journal of haematology.

[10]  E. Haddad,et al.  Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. , 2003, The Journal of pediatrics.

[11]  D. Mueller-Wiefel,et al.  von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. , 2003, Blood.

[12]  Kazuo Fujikawa,et al.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. , 2002, Blood.

[13]  H. Tsai.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura , 2002, Journal of Molecular Medicine.

[14]  T. Foroud,et al.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura , 2001, Nature.

[15]  B. Lämmle,et al.  Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. , 2001, Best practice & research. Clinical haematology.

[16]  H. Tsai.  Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. , 1996, Blood.

[17]  D. Deykin,et al.  Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. , 1982, The New England journal of medicine.

[18]  J. Upshaw.  Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. , 1978, The New England journal of medicine.